Novo Nordisk has been publicly reprimanded for a UK scheme in which it offered to pay thousands of community pharmacists to promote sales of its weight loss drug Saxenda, while at the same time concealing its involvement in the program.
Novo Nordisk Named And Shamed For Paying Pharmacists To Boost Weight Loss Drug Sales
Training Scheme Was Disguised Promotion, UK Watchdog Finds
The company has been publicly reprimanded for its training program for UK pharmacists, which the industry watchdog judged to be solely focused on increasing use of weight loss drug Saxenda
